natgillin/translations-raw huggingface dataset:
They were designated IL-18BP a, b, c and d, all sharing the same N-terminus and differing in the C-terminus (Novick et al, 1999). 
Označene su kao IL-18BP a, b, c i d, sa svima zajedničkim N-terminusom i s razlikama u C-terminusu (Novick et ali., 1999).
The bispecific antibody or antibody fragment according to claim 15, wherein the disease is selected from the group consisting of: a TH2-mediated disease, an IL-4 and/or IL-13 mediated disease, an allergic disease, asthma, cancer, an autoimmune disease, a disease associated with abnormal production of IL-4 and/or IL-13, scleroderma and idiopathic pulmonary fibrosis. 
Protutijelo ili fragment protutijela prema zahtjevu 12, naznačeno time da je bolest odabrana iz skupine koju čine alergijska bolest, astma, rak, autoimuna bolest, sklerodermija i idiopatska plućna fibroza.
one or more DNA polynucleotides encoding said DNA-targeting RNA are one or more recombinant expression vectors; and/or 
Jedna ili više nukleinskih kiselina prema zahtjevu 15, naznačene time, da navedene nukleinske kiseline predstavljaju jednoga ili više rekombinantnih vektora ekspresije.
The wine decanter device of one or more of the precedings claims 7 to 9, wherein said base (10) is provided with means (11) for perfect horizontal leveling. 
Uređaj za pretakanje vina iz jednog ili više prethodnih patentnih zahtjeva 7 do 9, u čemu, spomenuto postolje (10) sadrži sredstva (11) za savršeno horizontalno niveliranje.
The colored solar cell of the present invention comprises a photoelectric conversion substrate; at least one anti-reflection layer formed on the photoelectric conversion substrate; and two or more transparent inorganic dielectric layers which are formed on the anti-reflection layer, wherein the two or more transparent inorganic dielectric layers comprise at least one first transparent inorganic dielectric layer consisting of an oxide of titanium. 
HR P20182015 T1 PATENTNI ZAHTJEVI Obojena solarna stanica, koja sadrži supstrat za fotoelektričnu konverziju; najmanje jedan antirefleksijski sloj formiran na supstratu za fotoelektričnu konverziju; 1 dva ili više transparentnih anorganskih dielektričnih slojeva formiranih na antirefleksijskom/im sloju/slojevima, karakterizirana time, što dva ili više transparentnih anorganskih dielektričnih slojeva uključuje:
Sixty minutes after product administration, a paper patch saturated with FeCl3 solution (70%) was placed (and not removed for the whole duration of the experiment) on the left carotid artery downstream from the sounding of flow to initiate thrombosis. 
60 minuta nakon izdanog proizvoda, papirnati flaster zasićen otopinom FcCl3 (70%) stavljen je (i nije odstranjen cijelo vrijeme trajanja pokusa) na lijevu karotidnu arteriju silazno od ozvučenja protoka prema početnoj trombozi.
represents a benzene ring or a naphthalene ring, the ring being optionally substituted by 1 to 4 substituents selected from a C1-3 alkyl group, a halogen atom, a hydroxyl group or a C1-2 alkoxy group; and/or 
R2 predstavlja benzenski prsten ili naftalenski prsten, gdje su ti prsteni izborno supstituirani s 1 do 4 supstituenta, koje se bira između C,3 alkilne skupine, atoma halogena, hidroksilne skupine ili C;2 alkoksi skupine; i/ili
a second light chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:120 and SEQ ID NO:174. 
drugi laki lanac koji sadrži aminokiselinsku sekvencu odabranu iz skupine koja se sastoji od SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:120 i SEQ ID NO:174.
A package as claimed in claim 4, wherein the main wall (26) of the stiffener (25) is positioned contacting the front wall of the group (4) of cigarettes, and comprises a top window (28). 
Pakiranje u skladu s patentnim zahtjevom 4 ili 5, naznačeno time, da svako bočno krilo (27) elementa za učvršćivanje (25) sadrži gornji dodatak, koji se presavija na gornju stjenku skupine (4) cigareta.
The antibody or functional fragment of the antibody, or products for use according to claim 27 or the use according to claim 27, characterized in that the osteoporosis is postmenopausal osteoporosis, senile osteoporosis, secondary osteoporosis due to the use of a therapeutic agent such as a steroid or an immunosuppressant, or osteoporosis, accompanying rheumatoid arthritis. 
HR P20150485 T1 Antitijelo ili njegov funkcionalni fragment ili preparati za uporabu sukladno zahtjevu 27 ili uporaba sukladna zahtjevu 27, karakterizirani time da je osteoporoza postmenopauzalna osteoporoza, staračka osteoporoza, sekundarna osteoporoza uzrokovana uporabom terapeutika kao što su steroidi ili imunosupresivi, ili osteoporoza koja prati reumatoidni artritis.
(a1) an antigen-binding site comprising an H chain CDR 1, 2, and 3 having at least 70% sequence identity with amino acid sequences of SEQ ID NOs: 75, 76, and 77, respectively; 
(a1) mjesto vezanja antigena koje obuhvaća aminokiselinske sekvence H-lanca CDR-područja 1, 2 i 3 od SEQ ID NO: 75, 76 odnosno 77 (H-lanac CDR-područja od Q1);
The method according to claim 1, wherein R14 represents an unsubstituted phenyl group, or a phenyl group mono- or di-substituted substituted with methyl or lialogen, and R15 represents lower alkyl. 
Derivati tiazolidin-4-ona prema zahtjevima 4 do 9, naznačeni time, da R"" predstavlja nesupstituiranu, ili a mono- ili di-supstituiranu fenilnu skupinu, supstituiranu metilom ili halogenom, a R"* predstavlja niži alkil.
subjecting the dough to heating to above the denaturation temperature of the protein; subjecting the dough to shear forces and pressure in an extruder, so as to form a fibrous protein composition; 
(d) podvrgavanje tijesta silama siječenja 1 pritiska u ekstruderu, tako da tvore vlaknasti sastav proteina soje;
correlating the presence or absence of the immunological complex with the presence or absence of amyloid antigen in the sample or specific body part or area; and 
koreliranju prisutnosti ili odsutnosti imunološkog kompleksa s prisutnošću ili odsutnošću amiloidnog antigena u uzorku; i
Preferably the infusion time is about 1, 3 or 24 hours. 
Poželjno, vrijeme infuzije je oko 1, 3 ili 24 sata.
A reversible, short-acting P2Y12 inhibitor for use in a method of at least partially inhibiting platelet activities in a subject previously treated with at least one thienopyridine, wherein treatment with the at least one thienopyridine is discontinued prior to administering the reversible, short-acting P2Y12 inhibitor, wherein the reversible, short-acting P2Y12 inhibitor is cangrelor and is administered to the subject up to 5 days before an invasive procedure to be performed on the subject or during an invasive procedure being performed on the subject. 
Reverzibilni, kratko djelujući P2Y,> inhibitor za uporabu u postupku barem djelomične inhibicije aktivnosti trombocita kod subjekta koji je prethodno liječen s barem jednim tienopiridinom, pri čemu se liječenje s barem jednim tienopiridinom prekida prije davanja reverzibilnog, kratko djelujućeg inhibitora P2Y;,, naznačen time da reverzibilni, kratko djelujući inhibitor P2Y;> je cangrelor i daje se subjektu do 5 dana prije invazivnog postupka koji se provodi na subjektu ili tijekom invazivnog postupka koji se provodi na subjektu.
For this process, a suspension or a solution of the complete sugar replacement composition is prepared, after which it is atomized into a spray of droplets and contacted with hot air. 
Tim se postupkom pripremi kompletna sastavina koja zamjenjuje šećer i potom atomizira raspršivanjem u kapljice koje dolaze u dodir s vrućim zrakom.
The use according to any one of claims 1-4, wherein the medicament is suitable for oral administration. 
Oblik doziranja iz patentnog zahtjeva 9 ili patentnog zahtjeva 10, pri čemu je oblik doziranja pogodan za oralnu primjenu.
A composition for use according to claim 1, wherein a loading dose treatment period precedes the weekly application. 
Pripravak za primjenu prema patentnom zahtjevu 1, naznačen time, što razdoblje liječenja inicijalnom dozom prethodni tjednom nanošenju.
The use according to claims 5 to 7, wherein the calcitonin mimetic is for use in mitigating insulin resistance. 
Mimetik kalcitonina za primjenu sukladno patentnom zahtjevu 2, pri čemu je mimetik kalcitonina za primjenu u ublažavanju otpornosti na inzulin.
obtaining, from a bitstream, an x index indicating an x coordinate of a last significant coefficient, from among transformation coefficients of a current transformation block, among the at least one transformation block, and a y index indicating a y coordinate of the last significant coefficient; 
Postupak entropijskog dekodiranja koeficijenata transformacije, te postupak sadrži: dobivanje, iz toka bitova, indikator kodiranog bloka koji pokazuje da li u transformacijskom bloku postoji najmanje jedan značajni koeficijent transformacije koji ima vrijednost različitu od nula;
A pharmaceutical composition according to claim 24, wherein the coating layer comprises coating agents, plasticizers, antitacking agents, surfactants, coloring agents, opacifiers or mixtures thereof. 
Oralni farmaceutski pripravak s kontroliranim oslobađanjem u skladu sa zahtjevom 23, naznačen time da sloj obloge sadrži sredstva za oblaganje, plastifikatore, sredstva protiv sljepljivanja, površinski aktivne tvari, bojila, sredstva za postizanje neprozirnosti ili mješavine istih.
In some embodiments, the method comprises administering to the individual an effective amount of a composition comprising nanoparticles comprising paclitaxel and albumin. 
(a) djelotvornu količinu pripravka koji sadrži nanočestice koje sadrže taksan i protein-nosač, gdje je taksan paklitaksel, a gdje je protein-nosač albumin, i
The formulation according to claim 1 said formulation comprising a compound selected from the group comprising: 
Spoj prema patentnom zahtjevu 1, izabran iz grupe koja sadrži:
A kit comprising the inserter of claim 1 and the intrauterine system, wherein: 
Set koji obuhvaća aplikator za umetanje prema zahtjevu 1 i intrauterini sustav, gdje
the compound of formula (VIII) is subjected to a bromination reaction in order to obtain the compound of formula (X): 
spoj s formulom (VIII) se podvrgava reakciji bromiranja kako bi se dobilo spoj s formulom (X): [image]
The tablet of any one of embodiments 1-4 which comprises 200 ± 10.0 mg of emtricitabine. 
Tableta bilo kojeg od zahtjeva 1-3 koja sadrži 200 + 10.0 mg emtricitabina.
The method according to any one of claims 1 to 6, wherein the mammalian cells are CHO cells. The method according to any one of claims 1 to 7, wherein the continuous cultivation of cells is performed in chemostatic mode. The method according to any one of claims 1 to 7, wherein the continuous cultivation of cells is performed in perfusion mode. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što su jedna ili više stanica sisavačke stanice, po mogućnosti stanice CHO. Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što se uzgoj jedne ili više stanica sastoji u šaržnom uzgoju stanica ili u kontinuiranom uzgoju stanica.
The method of claim 1, wherein the amount of the first base ranges from about 1 to about 10, from about 2 to about 7 or from about 3 to about 6 molar equivalents per molar equivalent of the acylating agent. 
Postupak prema zahtjevu 1, naznačen time da je količina prve baze u rasponu od oko 1 do oko 10, od oko 2 do oko 7 ili od oko 3 do oko 6 molarnih ekvivalenata po molarnom ekvivalentu agensa za acililaranje.
wherein the feed stock contains no more than 0.01% of glass, metals, grit, and noncombustible waste and wherein the feed stock has an O/C ratio from 0.01 to 0.05. 
pri čemu tehničko gorivo ne sadržava više od 0,01 % stakla, metala, pijeska i negorivog otpada i pri čemu sirovina ima omjer O / C od 0,01 do 0,05.
Process according to Embodiment 1, characterized in that the condenser is a submerged condenser that is placed horizontally. 
Postupak sukladno zahtjevu 1, naznačen time što je kondenzator uronjeni kondenzator smješten vodoravno.
The dry sinsemilla cannabis inflorescence of any one of claims 1-6, wherein the first or second most abundant terpene in the terpene profile is selected from the group consisting of limonene, alpha humulene, and beta caryophyllene. 
Suha inflorescencija besjemenog kanabisa u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačena time što se prvi ili drugi najobilatiji terpen u terpenskom profilu bira iz skupine koju čine terpinolen, a-pinen, limonen, te B-kariofilen.
for use in the treatment of malignant haemopathies. 
namijenjen upotrebi u liječenju zloćudnih hemopatija.
An isolated nucleic acid encoding an interleukin (IL)-22 Fc fusion protein the IL-22 Fc fusion protein comprising an IL-22 polypeptide linked by a linker to an IgG4 Fc region that is not glycosylated, wherein the IL-22 Fc fusion protein binds to IL-22 receptor and comprises an amino acid sequence having at least 98% sequence identity to the amino acid sequence of SEQ ID NO:8, and wherein the linker consists of the amino acid sequence of RVESKYGPP (SEQ ID NO:44). 
Fuzijski protein Fc IL-22 koji se veže na receptor IL-22, naznačen time, da navedeni fuzijski protein Fc IL-22 obuhvaća polipeptid IL-22 povezan na Fc područje preko poveznice, pri čemu Fc područje obuhvaća zglobno područje, IgG domenu CH2 i IgG domenu CH3, gdje fuzijski protein Fc IL-22 sadrži aminokiselinsku sekvencu koja ima najmanje 95% identiteta sekvence prema aminokiselinskoj sekvenci odabranoj iz skupine koja se sastoji od SEQ ID NO:8 i SEQ ID NO:10, dok se ostatak N297 mijenja u Gly ili Ala i pritom se Fc područje ne glikozilira.
The sleeve 20 has a flange 44 at the top thereof, which flange engages on the operating fork 23 that can be moved up and down along the chill chamber 2 with the aid of the handle 25. 
Rukavac 20 ima prirubnicu 44 na svojem vrhu, koja zahvaća radnu vilicu 23 koja se može pomicati gore i dolje uzduž hladne komore 2 uz pomoć ručke 25.
iv) an acid with a pK lower than 6 as pH regulator and buffer, in a quantity ranging from 0.01% to 0.5% by weight, preferably ranging from 0.25% to 0.45% by weight with respect to the total weight of the additive composition; 
iv) kiselinu sa pK nižom od 6 kao pH regulatorom i puferom, u količini u rasponu od 0.01% do 0.5% masenih, poželjno u rasponu od 0.25% do 0.45% masenih u odnosu na ukupnu masu kompozicije aditiva;
wherein is selected from H or 5-F; 
R, jest odabran od sljedećih: H ili 5-F;
separating the resulting crystallized salt of (aS,BR)-6-bromo-a-[2-(dimethylamino)ethyl]-2-methoxy-a-1-naphthalenyl-B-phenyl-3-quinolineethanol and said resolution agent from the reaction mixture obtained under a); 
razdvajanje dobivene kristalizirane soli (aS,BR)-6-bromo-a-[2-(dimetilamino)etil]-2-metoksi-a-1-naftalenil-B-fenil-3-kinolinetanola i navedenog sredstva za razlučivanje iz reakcijske smjese dobivene u koraku a);
The pooling device of embodiment 18, wherein said fluid connection assembly [104] includes a second fluid check valve [110] being connected to said inlet port [18] of said pooling device [10] for selectively regulating the directional fluid flow of the fluid. 
Uređaj za objedinjavanje prema zahtjevu 6, naznačen time što navedeni sklop za spajanje fluida [104] sadrži drugi nepovratni ventil za tekućinu [110] koji je spojen na navedeni ulazni otvor [18] navedenog uređaja za objedinjavanje [10] za selektivno reguliranje usmjerenog fluidnog strujanja fluida.
The method according to Claim 19 wherein the group interacts with residues Asn818 and/or Asp 831 (HER1 numbering) or the corresponding residues in a different kinase of the ribose/phosphate binding pockets. 
Postupak prema zahtjevu 19, naznačen time što skupina interreagira sa ostacima Asn 818 i/ili Asp 831 (HER1 numeracija) ili odgovarajućim ostacima u različitoj kinazi džepova za vezivanje riboze i/ili fosfata.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody or antigen-binding fragment thereof of any one of claims 1 to 13. 
Farmaceutski pripravak koji se sastoji od farmaceutski prihvatljivog nositelja 1 terapeutski učinkovite količine antitijela ili antigen vezujućeg fragmenta istog prema jednom od zahtjeva 1 do 13.
The method as claimed in any of claim 52 wherein the oral dosage form has an apparent density of 0.5-1.5 g/mL. 
Postupak prema zahtjevu 18, naznačen time da se ukupna težina oralnog oblika doziranja sastoji od 0.5-70 tež.% sredstva za raspadanje.
The compound according to claim 1 or claim 2, wherein the salt is selected from hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, methanesulfonate, p -toluenesulfonate; sodium, potassium, calcium, ammonium salts; and ethylenediamine, ethanolamine, N, N -dialkylenethanolamine, triethanolamine and basic aminoacids salts. 
Sjedinjenje sa formulom I, ili njegova farmaceutski prihvatljiva sol ili estar: Formula I. Sjedinjenje prema patentnom zahtjevu 1, gdje je sol odabrana od hidroklorid, hidrobromid, hidrojodid, sulfat, nitrat, fosfat, acetat, trifluoroacetat, maleat, fumarat, citrat, oksalat, sukcinat, tartrat, malat, mandelat, metansulfonat, p-toluensulfonat, natrij, kalij, kalcij i amonij soli; etilendiamin, etanolamin, N,N-dial_kilen etanolamin, trietanolamin i soli baznih aminokiselina.
The siRNA according to claim 1, wherein 1 to 10 consecutive nucleotides excluding an overhang nucleotide from the 3' terminus of the sense strand of the siRNA are converted into DNA. 
SIRNA u skladu s patentnim zahtjevom 1, naznačena time, da se 1 do 10 uzastopnih nukleotida s iznimkom izbočenog nukleotida 12 3' terminusa sens lanca siRNA, pretvaraju u DNA.
electrodes wherein the electrodes are effective to receive and conduct an electric current and further effective to secure the device to an electric source such that the first side of the insertion section is proximate to the electric source; 
elektrode (104, 106), pri čemu su elektrode djelotvorne za prihvat i vođenje električne struje i dodatno su djelotvorne za osiguravanje uređaja na izvor električne struje, tako da je prva strana odsječka za umetanje najbliže izvoru električne struje;
A reactor according to claim 1, characterized in that the said oscillating mass comprises a single restricted environment consisting of a milling jar having an axis coincident with the direction of the oscillations, the jar being provided with ports for feeding (12A) the substances to be treated and ports for discharging (12B) the products obtained from the treatment, and in that stop valves are arranged at all of the said ports. 
Reaktor u skladu s patentnim zahtjevom 1, naznačen time što navedena oscilirajuća masa sadrži jedan ograničeni okoliš, koji se sastoji od posude za mljevenje, koja ima os koja se poklapa sa smjerom oscilacija, gdje posuda ima otvore za dodavanje (12A) tvari koje treba obraditi i otvore za pražnjenje (12B) produkata dobivenih obradom, te što se ventili za zatvaranje nalaze na svim navedenim otvorima.
reacting Compound (K) or a pharmaceutically acceptable salt thereof with acetaldehyde in the presence of a palladium catalyst comprising a mixture of bis(dibenzylideneacetone) palladium and a tertiary phosphine ligand, PR3, wherein R is C1-6 alkyl or C5-6 cycloalkyl to form Compound (M) or a pharmaceutically acceptable salt thereof, wherein X3 is Br or I; and 
* x? N" "NH, (K) ili njegove farmaceutski prihvatljive sol, s acetaldehidom u prisutnosti paladijskog katalizatora koji uključuje smjesu bis(dibenzilidenaceton)paladija s tercijarnim fosfinskim ligandom, PR*, gdje je R C,4 alkil ili Cs4 cikloalkil, kako bi se dobilo Spoj (M) x1 La) pe N
a second one of the wrappers defines a second flexible wrapper; 
drugi od omotača (40) definira drugi fleksibilni omotač (40);
The time threshold is a time that the user should reduce the speed of the vehicle 2 to below the imposed speed limit. In this regard, the compliance signal is generated all the time that the user is responding to the control signal, but if the user does not respond by performing enough of the correct action, then the time threshold ensures further action is taken to alert the driver to perform a further action. 
Sustav prema bilo kojem od prethodnih zahtjeva naznačen time što, se signal usklađenosti generira cijelo vrijeme dok korisnik odgovara na kontrolni signal, ali ako korisnik ne odgovara provođenjem dovoljno ispravnog djelovanja, radi dovoljnog ispravljanja trenutne brzine vozila tada vremenski prag osigurava da se poduzima daljnje djelovanje kako bi se vozač upozorio da izvrši daljnje djelovanje ili ponavljanjem kontrolnog signala, ili generiranjem drugog ili trećeg kontrolnog signala.
The compound according to claim 1 in a crystalline form. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound according to claim 1 in admixture with a pharmaceutically acceptable carrier. 
Farmaceutski pripravak, naznačen time što sadrži farmaceutski djelotvornu količinu spoja u skladu s patentnim zahtjevom 1 u smjesi s farmaceutski prihvatljivom podlogom.
Further disclosure regarding these nozzle arrangements can be found in WO 94/07607 A1 and WO 99/16530 A1. 
Daljnji opis što se tiče ovih naprava s mlaznicom može se naći u WO 94/07607 A1 i WO 99/16530 A1.
optionally a clopidogrel salt is converted into clopidogrel base, 
(a) opcijski se sol klopidogrela pretvara u bazu klopidogrela,
A method of detecting a fetal cell comprising the steps of 
Postupak detektiranja fetalne stanice koji sadrži korake
This separation allows disposal of the various layers according to the criteria of sorted waste collection. 
To rastavljanje omogućuje odlaganje različitih slojeva prema kriterijima za skupljanje razvrstanog otpada.
The process of claim 1, wherein the effective amount of time is 2 to 24 hours. 
Postupak iz zahtjeva 26, naznačen time da je učinkovita količina vremena 2 do 24 sata.
The compound according to claim 1, wherein said compound has formula (III): or a pharmaceutically acceptable salt thereof, wherein independently for each occurrence: 
j < LA o aa, z oi, Spoj prema zahtjevu 1, pri čemu navedeni spoj ima formulu (III):
In respect of the in vivo imaging, in one preferred embodiment the present invention provides said IAPP and/or proIAPP binding molecule comprising at least one CDR of an antibody of the present invention, wherein said in vivo imaging comprises positron emission tomography (PET), single photon emission tomography (SPECT), near infrared (NIR) optical imaging or magnetic resonance imaging (MRI). 
Antitijelo za uporabu u skladu s patentnim zahtjevom 15, naznačeno time, da navedena in vivo detekcija sadržava pozitronsku emisijsku tomografiju (PET), tomografiju emisijom jednog fotona (SPECT), optičko snimanje u blizini infracrvenog spektra (NIR) ili magnetsku rezonanciju (MRI) 1 / ili pri čemu je antitijelo pripravljeno za upotrebu u postupku u skladu s patentnim zahtjevom 14.
a complementarity determining region light chain 1 (CDRL1) amino acid sequence selected from the group consisting of SEQ ID NOS:46-51; 
komplementarnu određujuću regiju lakog lanca 1 (CDRL1) aminokiselinsku sekvencu od SEQ ID NO:50;
and a pharmaceutically acceptable salt thereof. A compound of claim 1, wherein said compound is 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; or a pharmaceutically acceptable salt thereof. 
Upotreba spoja koji je 3-ciklopentil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propionitril, ili njegova farmaceutski prihvatljiva sol, naznačen time da je za pripremu lijeka za liječenje raka gušterače, raka dojke, raka pluća, ili raka glave i vrata.
The compound of claim 11, wherein the skeletal muscular disorders and diseases are selected from the group consisting of skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence. 
Uporaba prema patentnom zahtjevu 1, naznačena time što su poremećaji i bolesti skeletnih mišića povezani s RyR izabrani iz grupe koju čine zamor skeletnog mišića, zamor skeletnog mišića induciran povećanom fizičkom aktivnošću, mišićna distrofija, poremećaji mokraćnog mjehura i inkontinencija.